ArticleJournal of translational medicine2026
A humanized LIF-targeting antibody synergistically enhances chemo- and immunotherapy in pancreatic cancer.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPancreatic cancer is associated with a low survival rate due to its late diagnosis, and the patients’ resistance to chemotherapy and immunotherapy. Leukemia inhibitory factor (LIF), a member of the interleukin-6 (IL-6) cytokine family, promotes the development and progression of pancreatic cancer and has emerged as a promising therapeutic target. Here, our objectives were to validate the druggability of LIF as a therapeutic target and establish an innovative treatment strategy for pancreatic ductal adenocarcinoma (PDAC) by leveraging antibody-mediated LIF blockade to enhance the efficacy of gemcitabine-based chemotherapy or PD-1-targeted immunotherapy.
methodWe generated a humanized anti-LIF antibody using a murine framework as the basis. To minimize immunogenicity, we performed structural optimization of VL/VH domains and employed rational design strategies. Surface plasmon resonance (SPR) was used to determine the binding affinity of the antibody for the LIF antigen. Antitumor efficacy was evaluated across multiple preclinical models, including cancer cell lines, patient-derived organoids (PDOs), cell-derived xenografts（CDXs）, and patient-derived organoid xenografts (PDOXs). The humanized anti-LIF (h-anti-LIF) antibody was co-administered with either chemotherapy or immunotherapy in these models to assess the impact of the combination on tumor growth.
resultsThe h-anti-LIF antibody demonstrated higher specificity and affinity for LIF compared with its murine counterpart and exhibited superior efficacy in inhibiting tumor growth relative to the murine antibody. Furthermore, our findings revealed that selective targeting of LIF not only enhanced the chemosensitivity of pancreatic cancer to gemcitabine but also improved the efficacy of PD-1-targeted immunotherapy.
conclusionOur study demonstrates that the humanized anti-LIF antibody emerges as a promising adjuvant for enhancing the efficacy of both chemotherapy and immunotherapy in pancreatic cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.